Newscasts - Novo Nordisk says WeightWatchers will sell Wegovy

Hims

27/06/2025 09:59

Click the following link to watch video: https://share.newscasts.refinitiv.com/link?entryId=1_fjd3k2x6&referenceId=tag:reuters.com,2025:newsml_RW553627062025RP1_930&pageId=Newscasts
Source: 'Reuters - Business videos'

Description: Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1. Ciara Lee reports.

Short Link: https://refini.tv/3ZTNEOJ

Video Transcript:

Novo Nordisk is to collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy. Under the deal to start on July 1, cash-paying patients can access a month's supply of Wegovy through the Danish drugmaker's NovoCare Pharmacy for $299. Novo recently announced the end of its collaboration with Hims & Hers Health. It cited the telehealth platform's sales of Wegovy copies and marketing tactics. WeightWatchers, which has exited bankruptcy, says it no longer offers compounded versions of semaglutide. That's the active ingredient in Wegovy. Novo said it is maintaining deals with WeightWatchers rivals Ro and LifeMD. WeightWatchers, intending to shed over $1 billion in debt, filed for Chapter 11 bankruptcy relief in May as part of a restructuring plan. In court documents, the company said its weight management program faced competition from sales of drugs like Wegovy. Demand for cheaper compounded versions of popular weight-loss drugs have risen over the past two years. After its deal with Novo fell apart, Hims' CEO in a statement this week accused the drugmaker of attempting to steer patients toward the branded version of Wegovy.